OncoMatch/Lymphoma — Diffuse Large B-Cell (DLBCL)/MYC rearrangement
Lymphoma — Diffuse Large B-Cell (DLBCL)MYC rearrangement Clinical Trials
MYC rearrangements occur in approximately 10% of DLBCL; when co-occurring with BCL2 and/or BCL6 rearrangements (double/triple hit lymphoma), they define high-grade B-cell lymphoma with very poor prognosis on R-CHOP. DA-EPOCH-R is commonly used for double/triple-hit lymphoma despite limited randomized data. Trials investigate intensive induction regimens, polatuzumab vedotin combinations, CAR-T cell therapy in the first-line setting, and novel targeted approaches for MYC-rearranged aggressive lymphoma.
Top recruiting MYC rearrangement Lymphoma — Diffuse Large B-Cell (DLBCL) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Nordic Lymphoma Group
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
More MYC rearrangement Lymphoma — Diffuse Large B-Cell (DLBCL) trials
8 international trials (no US sites)
Browse other molecular targets with active Lymphoma — Diffuse Large B-Cell (DLBCL) trials.